Summary & Overview
HCPCS J7627: Budesonide Inhalation Solution, Compounded, DME Unit Dose
HCPCS Level II code J7627 denotes a compounded unit-dose inhalation solution of budesonide (up to 0.5 mg) intended for administration through durable medical equipment. The code identifies a nebulized corticosteroid product prepared as a compounded medication and supplied in single-use doses. Nationally, use of compounded inhalation agents intersects clinical needs for tailored dosing and supply-chain or formulation constraints, and it has implications for coverage, DME coordination, and pharmacy compounding policies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code's clinical context and service setting, typical payer considerations, and the types of benchmarks and policy elements commonly associated with HCPCS drug supply codes. The publication highlights reimbursement and billing practice themes relevant to compounded DME-administered inhalation medications, documentation and claim line considerations, and how this code relates to broader medication and DME coverage policies.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service-line specifics.
Billing Code Overview
HCPCS Level II code J7627 describes budesonide inhalation solution, compounded product, administered through durable medical equipment (DME), unit dose form, up to 0.5 mg. This code represents a compounded inhaled corticosteroid formulation prepared for nebulized delivery and supplied in unit-dose packaging.
Service Type: Nebulized inhalation therapy (compounded medication) administered via DME
Typical Site of Service: Home or outpatient settings where durable medical equipment (nebulizers) is used for inhalation therapy, including home health administration and clinic-based DME use.
Clinical & Coding Specifications
Clinical Context
A pediatric patient with moderate persistent asthma presents to a pulmonary clinic for initiation of inhaled corticosteroid therapy. The clinician prescribes compounded budesonide inhalation solution in unit-dose form to be administered via the patient’s home nebulizer (durable medical equipment). The compounded unit-dose J7627 (budesonide, inhalation solution, compounded product, administered through DME, unit dose form, up to 0.5 mg) is prepared by a pharmacy and delivered with instructions for nebulizer use. The clinical workflow includes: outpatient assessment and documentation of indications (worsening wheeze, increased rescue inhaler use, nocturnal symptoms), prescription of nebulized budesonide, verification of patient’s DME suitability and home environment, coordination with the pharmacy to compound and label unit-dose vials, billing of the medication using J7627 when dispensed/administrated through the DME pathway, and follow-up to assess response and adherence. Typical sites of service include outpatient pulmonary clinics, home health settings when DME is used for administration, and ambulatory infusion or respiratory therapy units attached to DME services. Patient scenario example: a 6-year-old child with asthma exacerbations who cannot reliably use a metered-dose inhaler with spacer; the clinician orders nebulized budesonide in unit-dose vials to be administered at home via the family’s nebulizer (DME).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|